Yelin Lapidot Holdings Management’s GSK GSK Stock Holding History

Yelin Lapidot Holdings Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.64M	Hold	88,500	–	–	0.88%	31
2026 Q1	$4.88M	Hold	88,500	–	–	1.02%	27
2025 Q4	$4.34M	Hold	88,500	–	–	0.87%	29
2025 Q3	$3.82M	Sell	88,500 -275,553	-76%	-$10.8M	0.8%	30
2025 Q2	$14M	Sell	364,053 -40,380	-10%	-$1.54M	2.55%	11
2025 Q1	$15.7M	Buy	404,433 +88,500	+28%	+$3.24M	3.03%	9
2024 Q4	$10.7M	Buy	315,933 +253,320	+405%	+$9.12M	1.86%	15
2024 Q3	$2.56M	Sell	62,613 -3,515	-5%	-$144K	0.42%	41
2024 Q2	$2.55M	Hold	66,128	–	–	0.45%	41
2024 Q1	$2.83M	Hold	66,128	–	–	0.58%	39
2023 Q4	$2.47M	Hold	66,128	–	–	0.6%	36
2023 Q3	$2.43M	Buy	+66,128	New	+$2.35M	0.6%	39

Other funds holding GSK

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

MHI

Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Yelin Lapidot Holdings Management's GSK Position: Q2 2026 in Review

Yelin Lapidot Holdings Management held its GSK (GSK) position steady in Q2 2026 at 88,500 shares worth $4.64M. The position accounts for 0.88% of the portfolio, ranked #31.

Yelin Lapidot Holdings Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $15.7M in Q1 2025. 475 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Yelin Lapidot Holdings Management held 88,500 shares of GSK worth $4.64M as of Q2 2026.
Yelin Lapidot Holdings Management left its GSK share count unchanged in Q2 2026.
GSK made up 0.88% of Yelin Lapidot Holdings Management's portfolio in Q2 2026, its #31 holding.
Yelin Lapidot Holdings Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Yelin Lapidot Holdings Management's GSK position peaked at $15.7M in Q1 2025.
475 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Yelin Lapidot Holdings Management's 13F filing for Q2 2026, filed 3 Aug 2026.